(3R,4S,5S,6R)-6-(Hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,4,5-triol

Term ID

CHEBI:150425

Synonyms

beta-D-galacto-hexopyranosyl-(1->6)-alpha-D-manno-hexopyranosyl-(1->2)-D-gluco-hexopyranose
Gal(b1-6)Man(a1-2)Glc

Definition

References

glytoucan:G39055CL

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4S,5S,6R)-6-(Hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,4,5-triol

Phenotype where environments contain (3R,4S,5S,6R)-6-(Hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,4,5-triol

Phenotype modified by environments containing (3R,4S,5S,6R)-6-(Hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,4,5-triol

Phenotype affecting (3R,4S,5S,6R)-6-(Hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,4,5-triol

Human Disease Model